Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
Clostridioides Difficile Colonisation
- Conditions
- Clostridioides Difficile Infection
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT05693077
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
- Conditions
- Immunotherapy
- Interventions
- Drug: Fecal microbiota transferDrug: Placebo Vancomycin Oral CapsuleDrug: Placebo Fecal microbiota transfer
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Michael Dill
- Target Recruit Count
- 48
- Registration Number
- NCT05690048
- Locations
- 🇩🇪
University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany
Impact of Prophylactic Antibiotics on Bloodstream Infections After Liberation From Extracorporeal Membrane Oxygenation
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Universität des Saarlandes
- Target Recruit Count
- 42
- Registration Number
- NCT05651464
- Locations
- 🇩🇪
University Hospital of Saarland, Homburg, Saarland, Germany
The Effect of Intrawound Vancomycin Powder on Surgical Site Infection in Inguinal Lymph Node Dissection
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Women and Infants Hospital of Rhode Island
- Target Recruit Count
- 30
- Registration Number
- NCT05625373
- Locations
- 🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States
Linezolid or Vancomycin Surgical Site Infection Prophylaxis
- Conditions
- Antibiotic ProphylaxisGeneral Surgery
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 1160
- Registration Number
- NCT05571722
- Locations
- 🇫🇷
Anesthésie Réanimation - Hôpital Nord (AP-HM), Marseille, France
Vancomycin Study in Multiple Sclerosis (MS)
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 12
- Registration Number
- NCT05539729
- Locations
- 🇺🇸
Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New York, New York, United States
Model-informed Precision Dosing of Vancomycin in Adults
- Conditions
- Vancomycin
- Interventions
- Device: Vancomycin model-informed precision dosing
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 155
- Registration Number
- NCT05535075
- Locations
- 🇧🇪
Ghent University Hospital, Ghent, Belgium
🇧🇪General Hospital Sint-Jan Brugge, Brugge, Belgium
A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD
- Conditions
- Primary Sclerosing CholangitisInflammatory Bowel Diseases
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- University Hospital Birmingham NHS Foundation Trust
- Target Recruit Count
- 15
- Registration Number
- NCT05376228
- Locations
- 🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
- Conditions
- Ulcerative ColitisColitis, Ulcerative
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05370885
- Locations
- 🇺🇦
Medical Center OK!Clinic+, Kyiv, Ukraine
🇺🇸Clinical Applications Laboratories, San Diego, California, United States
🇺🇸GI Pros Research, Naples, Florida, United States
Topical Antibiotics in Surgical Site
- Conditions
- Complication of Surgical ProcedureSurgical Site Infection
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Universidad Autonoma de Nuevo Leon
- Target Recruit Count
- 75
- Registration Number
- NCT05363462
- Locations
- 🇲🇽
Hospital Universitario "Dr. José E. González", Monterrey, NL, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.